Form 4: Director Nancy Miller-Rich Acquires 50,000 Stock Options

Nancy Miller-Rich, a Director at 4D Molecular Therapeutics, Inc., was granted 50,000 stock options as part of the company's non-employee director compensation program.

Summary

• Nancy Miller-Rich, a Director at 4D Molecular Therapeutics, Inc. (FDMT), received a grant of 50,000 stock options on June 17, 2026.
• These options were automatically granted under the company's non-employee director compensation program.
• The stock options have an exercise price of $9.42 and an expiration date of June 16, 2036.
• Vesting of the options occurs in stages: one-third on June 17, 2027, with the remainder vesting in equal monthly installments until fully vested on June 17, 2029, contingent upon continued service.
• A Change in Control event, as defined by the 2020 Incentive Award Plan, would also trigger full vesting of these options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development.

Positives

• Director compensation aligns with long-term company performance through stock options.
• The grant of options indicates continued confidence in the company's future prospects by its directors.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the stock options is subject to market fluctuations and the company's stock performance.
• Vesting is contingent on continued service, meaning the director could forfeit unvested options if service is terminated.
• A Change in Control event, while triggering vesting, could also signify a significant change in the company's strategic direction or ownership.

Future Outlook

The stock options are exercisable with a portion vesting annually through June 17, 2029, and fully vesting upon a Change in Control, indicating a long-term outlook tied to company performance and potential strategic events.

Industry Context

StockSavvy.ai notes that the automatic grant of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical sectors, aligning director incentives with shareholder value and long-term company growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: This filing is a standard disclosure and does not directly impact employees, though it reflects the company's compensation structure.
• Management: Reinforces the standard compensation framework for non-employee directors.

Next Steps

• Continued service by Nancy Miller-Rich through the vesting dates.
• Potential exercise of stock options upon vesting or after a Change in Control event.

Key Dates

Keywords

stock options, director compensation, 4D Molecular Therapeutics, FDMT, insider trading, Form 4, equity award, vesting schedule, beneficial ownership